Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets

Transfusion and Apheresis Science

Volumn 49, Issue 2, 2013, Pages 285-290

  Mastroianni, Maria Adele ^a   Llohn, Abid Hussain ^a   Akkök, Çiǧdem Akalin ^b   Skogheim, Ruby ^a   Ødegaard, Elna Rathe ^a   Nybruket, Monica Jenssen ^a   Flesland, Annika ^a   Mousavi, Seyed Ali ^a  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

In vitro platelet quality; MCS+ apheresis platelets; Mirasol pathogen reduction technology

Indexed keywords

GLUCOSE; LACTIC ACID; PADGEM PROTEIN; THROMBOCYTE CONCENTRATE;

ADULT; ARTICLE; BACTERIAL GROWTH; BACTERIAL TRANSMISSION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); FEMALE; GENERAL MEDICAL DEVICE; GLUCOSE INTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE COUNT; MALE; MIRASOL PATHOGEN REDUCTION TECHNOLOGY SYSTEM; PH; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; STORAGE TEMPERATURE; THROMBOCYTE ACTIVATION; THROMBOCYTE PRESERVATION; THROMBOCYTE SHAPE; THROMBOCYTOPHERESIS;

IN VITRO PLATELET QUALITY; MCS+ APHERESIS PLATELETS; MIRASOL PATHOGEN REDUCTION TECHNOLOGY;

BLOOD PLATELETS; BLOOD PRESERVATION; BLOOD SAFETY; DISINFECTION; FEMALE; GLUCOSE; HUMANS; HYDROGEN-ION CONCENTRATION; LACTIC ACID; MALE; PLATELETPHERESIS;

EID: 84886640310     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2013.06.009     Document Type: Article

References (30)

1. Marschner S., Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011, 38:8-18.
2. Palavecino E.L., Yomtovian R.A., Jacobs M.R. Bacterial contamination of platelets. Transf Apheresis Sci: Off J World Apheresis Assoc: Off J Eur Soc Haemapheresis 2010, 42:71-82.
3. Perkins H.A., Busch M.P. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion 2010, 50:2080-2099.
4. Wagner S.J. Transfusion-transmitted bacterial infection: risks, sources and interventions. Vox Sanguinis 2004, 86:157-163.
5. Brown C.J., Navarrete C.V. Clinical relevance of the HLA system in blood transfusion. Vox Sanguinis 2011, 101:93-105.
6. Blajchman M.A., Goldman M., Baeza F. Improving the bacteriological safety of platelet transfusions. Transf Med Rev 2004, 18:11-24.
7. Solheim B.G., Seghatchian J. The six questions of pathogen reduction technology: an overview of current opinions. Transf Apheresis Sci: Off J World Apheresis Assoc: Off J Eur Soc Haemapheresis 2008, 39:51-57.
8. Mathai J. Problem of bacterial contamination in platelet concentrates. Transf Apheresis Sci: Off J World Apheresis Assoc: Off J Eur Soc Haemapheresis 2009, 41:139-144.
9. Gathof B.S., Tauszig M.E., Picker S.M. Pathogen inactivation/reduction of platelet concentrates: turning theory into practice. ISBT Sci Ser 2010, 5:114-119.
10. Goodrich R.P., Edrich R.A., Li J., Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transf Apheresis Sci: Off J World Apheresis Assoc: Off J Eur Soc Haemapheresis 2006, 35:5-17.
11. Klein H.G., Bryant B.J. Pathogen-reduction methods: advantages and limits. ISBT Sci Ser 2009, 4:154-160.
12. Janetzko K., Hinz K., Marschner S., Goodrich R., Kluter H. Pathogen reduction technology (Mirasol) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS. Vox Sanguinis 2009, 97:234-239.
13. Johnson L., Winter K.M., Reid S., Hartkopf-Theis T., Marschner S., Goodrich R.P., et al. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sanguinis 2011, 101:208-214.
14. Ostrowski S.R., Bochsen L., Salado-Jimena J.A., Ullum H., Reynaerts I., Goodrich R.P., et al. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2010, 50:2210-2219.
15. Picker S.M., Steisel A., Gathof B.S. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008, 48:1685-1692.
16. Cookson P., Thomas S., Marschner S., Goodrich R., Cardigan R. In vitro quality of single-donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days. Transfusion 2012, 52:983-994.
17. Kilkson H., Holme S., Murphy S. Platelet metabolism during storage of platelet concentrates at 22 degrees C. Blood 1984, 64:406-414.
18. Evaluation of stored platelets. Vox Sanguinis. 2004; 86: 203-23.
19. Gyongyossy-Issa M.I. Glucose in platelet additive solutions: to add or not to add?. Transfus Apheresis Sci: Off J World Apheresis Assoc: Off J Eur Soc Haemapheresis 2011, 44:283-295.
20. Cardo L.J., Rentas F.J., Ketchum L., Salata J., Harman R., Melvin W., et al. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sanguinis 2006, 90:85-91.
21. Cardo L.J., Salata J., Mendez J., Reddy H., Goodrich R. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apheresis Sci: Off J World Apheresis Assoc: Off J Eur Soc Haemapheresis 2007, 37:131-137.
22. Fast L.D., DiLeone G., Marschner S. Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Transfusion 2011, 51:1397-1404.
23. Tonnetti L., Proctor M.C., Reddy H.L., Goodrich R.P., Leiby D.A. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion 2010, 50:1019-1027.
24. Vanlandingham D.L., Keil S.D., Horne K.M., Pyles R., Goodrich R.P., Higgs S. Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Transfusion 2013, 53:284-290.
25. AuBuchon J.P., Herschel L., Roger J., Taylor H., Whitley P., Li J., et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005, 45:1335-1341.
26. Goodrich R.P., Li J., Pieters H., Crookes R., Roodt J., Heyns Adu P. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sanguinis 2006, 90:279-285.
27. Picker S.M., Oustianskaia L., Schneider V., Gathof B.S. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction. Vox Sanguinis 2009, 97:26-33.
28. Schubert P., Culibrk B., Coupland D., Scammell K., Gyongyossy-Issa M., Devine D.V. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage. Transfusion 2012, 52:397-408.
29. Castrillo A., Cardoso M., Rouse L. Treatment of buffy coat platelets in platelet additive solution with the mirasol((R)) pathogen reduction technology system. Transfus Med Hemotherapy: Offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin Immunhamatologie 2013, 40:44-48.
30. Reikvam H., Marschner S., Apelseth T.O., Goodrich R., Hervig T. The Mirasol Pathogen reduction technology system and quality of platelets stored in platelet additive solution. Blood transfusion =Trasfusione del sangue 2010, 8:186-192.